Idorsia to debut
at the 39th J.P. Morgan
Healthcare Conference
Positive results in second
pivotal study with
daridorexant for
patients with
insomnia
There’s more to Idorsia
than meets the eye!
Read the interview with
our CEO & CSO to get to
the bottom of the story...
Our key assets have
the potential to
transform treatment in
the target indications...
Idorsia today
The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.
Idorsia People
Idorsia’s success depends on its people.
Target diseases
Idorsia's development compounds target a number of different diseases.
News
| 11 Jan 2021 | |
| 23 Nov 2020 | |
| 27 Oct 2020 |
Events
| Event | When |
| Full-Year 2020 Financial Results reporting* | February 4, 2021 |
| First Quarter 2021 Financial Results reporting* | April 22, 2021 |
| Annual General Meeting of Shareholders | May 12, 2021 |
| Half-Year 2021 Financial Results reporting* | July 27, 2021 |
*We will be in a silent period for 10 days ahead of the financial reporting.
Shareprice
Contact
Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil
Switzerland
- +41 58 844 00 00
- Contact us online
- How to get to us